Trials / Terminated
TerminatedNCT03949673
Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip
Study to Evaluate Arthroplasty Specimens in the Phase 3 Fasinumab Program for Osteoarthritis of the Knee and Hip
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this exploratory study is to evaluate the cellular and connective tissue composition of joints from patients with Osteoarthritis (OA) who have been treated with fasinumab, compared with those treated with placebo or Non-steroidal anti-inflammatory drugs (NSAIDs).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fasinumab | Study drug will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study |
| DRUG | Naproxen | Naproxen will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study |
| DRUG | Diclofenac | Diclofenac will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study |
| DRUG | Celecoxib | Celecoxib will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study |
| DRUG | Placebo | Matching Placebo will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study |
Timeline
- Start date
- 2019-04-08
- Primary completion
- 2020-08-25
- Completion
- 2020-08-25
- First posted
- 2019-05-14
- Last updated
- 2023-10-17
- Results posted
- 2023-10-17
Locations
15 sites across 3 countries: United States, Poland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03949673. Inclusion in this directory is not an endorsement.